Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M133,501Revenue (TTM) $M23,050Net Margin (%)35.5Altman Z-Score3.0
Enterprise Value $M129,336EPS (TTM) $11.0Operating Margin %44.7Piotroski F-Score7
P/E(ttm)16.7Beneish M-Score-2.5Pre-tax Margin (%)42.1Higher ROA y-yY
Price/Book4.210-y EBITDA Growth Rate %12.8Quick Ratio5.8Cash flow > EarningsY
Price/Sales5.95-y EBITDA Growth Rate %20.3Current Ratio6.2Lower Leverage y-yN
Price/Free Cash Flow14.0y-y EBITDA Growth Rate %12.8ROA % (ttm)10.5Higher Current Ratio y-yY
Dividend Yield %2.4PEG0.8ROE % (ttm)26.7Less Shares Outstanding y-yY
Payout Ratio %39.0Shares Outstanding M730ROIC % (ttm)31.7Gross Margin Increase y-yY

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

AMGN is held by these investors:

AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Harper Sean EEVP, Research & Development 2017-10-09Sell1,525$185.95-1.61view
BALTIMORE DAVIDDirector 2017-05-31Sell3,700$153.9318.86view
Patton Cynthia MSVP & CCO 2017-05-24Sell2,922$154.418.5view
Such Annette LouiseVP, Finance and CAO 2016-08-02Sell3,000$174.594.79view
Balachandran MadhavanEVP, Operations 2016-05-04Sell30,000$154.1218.71view
Harper Sean EEVP, Research & Development 2016-04-29Sell21,875$157.9915.8view
BALTIMORE DAVIDDirector 2016-04-29Sell3,312$157.2116.38view
Bradway Robert AChairman, CEO and President 2016-03-02Sell20,000$146.4824.9view
de Carbonnel FrancoisDirector 2015-08-31Sell5,000$153.8418.93view
Hassan FredDirector 2015-08-19Buy3,010$166.639.8view

Press Releases about AMGN :

Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    Amgen And Boston Children's Hospital Enter A Collaboration To Find New Genes And Drug Targets For Se Oct 16 2017 
    Amgen Foundation Awards Khan Academy $3 Million To Support Development Of Free Comprehensive Biology Oct 12 2017 
    Mylan Receives FDA's CRL for Neulasta Biosimilar Oct 11 2017 
    FDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-In Oct 09 2017 
    Amgen And LabCentral Open Nomination Process For Lab Residency Oct 06 2017 
    First Randomized Study To Evaluate IMLYGIC® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, Oct 05 2017 
    Amgen, CytomX Join in Immuno-Oncology Collaboration Oct 04 2017 
    Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology Oct 03 2017 
    AbbVie, Amgen Resolve Humira Patent Dispute Sep 29 2017 
    Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA™ Sep 28 2017 

    More From Our Partners
    What's in the Cards for Amgen (AMGN) this Earnings Season? Oct 20 2017 - ZACKS
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat